论文信息 - P1-17-05: Preliminary Results of a Randomized Phase 2 Study of PD 0332991, a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole for First-Line Treatment of Patients (pts) with Post-Menopausal, ER+, HER2−Negative (HER2–) Advanced Breast Cancer. - 字舞流文

P1-17-05: Preliminary Results of a Randomized Phase 2 Study of PD 0332991, a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole for First-Line Treatment of Patients (pts) with Post-Menopausal, ER+, HER2−Negative (HER2–) Advanced Breast Cancer.

D. Amadori | R. Finn | T. Pintér | J. Crown | I. Láng | D. Slamon | H. Lim | Maike Schmidt | C. Hagenstad | S. Randolph | K. Boér | J. Walshe | A. Breazna | Sindy T. Kim | D. Chan | R. Dichmann | Ravi B. Patel | R. Parikh